Oligonucleotide Therapeutics: Case Studies, Current Industry Recommendations, & Future Perspectives
- Detection and risk assessment of hybridization-mediated off-targets
- Current strategic recommendations from an industrial perspective
- Pending challenges and the need for enhanced specificity and selectivity’